Gene Merutka is the Senior Vice President of Chemistry, Manufacturing and Controls (CMC) and Operations at Sapience Therapeutics. Dr. Merutka has over 25 years of experience in the biopharmaceutical industry and specializes in the development of peptide therapeutics, including CMC, preclinical, quality and regulatory CMC. Prior to his role with Sapience, Dr. Merutka co-founded and served as Vice President and Head of Non-Clinical Development and CMC at Merganser Biotech, Inc., which was developing a Hepcidin mimetic to treat iron storage diseases. Previously, he served as the Head of CMC Development and Vice President at Azelon Pharmaceuticals, Inc. (alternate name Zelos Therapeutics Inc.), where he focused on novel formulations and delivery routes for parathyroid hormone (PTH 1-34). He also worked at Vicuron Pharmaceuticals, where he was responsible for product development and played an important role in the submission of two approved NDA filings, and at Trimeris Inc., where he was part of the team that developed Fuzeon (Enfuvirtide).
Dr. Merutka holds a Ph.D. in Biochemistry from The University of Iowa and a B.S. in Chemistry from The University of Chicago. He completed a post-doctoral fellowship at The Scripps Research Institute.